Yahoo
HKSE - Delayed Quote HKD

Hua Medicine (Shanghai) Ltd. (2552.HK)

2.170 -0.005 (-0.23%)
At close: 4:08:13 PM GMT+8
Chart Range Bar
Loading chart for 2552.HK
  • Previous Close 2.175
  • Open 2.175
  • Bid 2.175 x --
  • Ask 2.185 x --
  • Day's Range 2.165 - 2.235
  • 52 Week Range 1.970 - 3.940
  • Volume 623,500
  • Avg. Volume 1,284,964
  • Market Cap (intraday) 2.167B
  • Beta (5Y Monthly) 0.84
  • PE Ratio (TTM) --
  • EPS (TTM) -0.130
  • Earnings Date --
  • Forward Dividend & Yield -- (0.00%)
  • Ex-Dividend Date --
  • 1y Target Est 4.56

Hua Medicine (Shanghai) Ltd. engages in the development and commercialization of drugs for the treatment of diabetes in China. The company develops HuaTangNing (Dorzagliatin or HMS5552), an oral drug for the treatment of Type 2 Diabetes (T2D); and Dorzagliatin in combination with Metformin, Sitagliptin, and Empagliflozin for treatment of T2D and DKD. It also provides Dorzagliatin in combination with GLP1RA and small molecule GLP-1 for T2D and obesity; combination with insulin to treat insulin sparing in T2D; second generation glucokinase (GK) inhibitor and GK NAM for metabolic disease; mGLUR5 negative allosteric modulator (NAM) for PD-LID and drug addiction; and Dorzagliatin for the treatment of T2D-Drug Naïve, T2D-Metformin Tolerated, RWE study for Diabetes Remission, MODY-2, Diabetes prevention IGT2NGT, Frailty, Early AD, and CFRD. Hua Medicine (Shanghai) Ltd. was incorporated in 2011 and is headquartered in Shanghai, China.

www.huamedicine.com

424

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Recent News

View More

Performance Overview

Trailing total returns as of 11/2/2026, which may include dividends or other distributions. Benchmark is HANG SENG INDEX (^HSI) .

YTD Return

2552.HK
29.08%
HANG SENG INDEX (^HSI)
8.73%

1-Year Return

2552.HK
38.53%
HANG SENG INDEX (^HSI)
9.70%

3-Year Return

2552.HK
40.00%
HANG SENG INDEX (^HSI)
35.77%

5-Year Return

2552.HK
44.07%
HANG SENG INDEX (^HSI)
6.80%

Analyst Insights

View More

Analyst Price Targets

3.55
4.56 Average
2.170 Current
5.57 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Statistics

View More

Valuation Measures

Annual
  • Market Cap

  • Enterprise Value

  • Trailing P/E

  • Forward P/E

  • PEG Ratio (current)

  • Price/Sales (ttm)

  • Price/Book (mrq)

  • Enterprise Value/Revenue

  • Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -16.47%

  • Return on Assets (ttm)

    -4.53%

  • Return on Equity (ttm)

    -10.51%

  • Revenue (ttm)

    654.41M

  • Net Income Avi to Common (ttm)

    -107.79M

  • Diluted EPS (ttm)

    -0.130

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    1.07B

  • Total Debt/Equity (mrq)

    35.69%

  • Levered Free Cash Flow (ttm)

    -7M

Company Insights

Research Reports

View More

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: